AIRNA Presents Data Supporting RNA Editing Approach for Alpha-1 Antitrypsin Deficiency (AATD) at 28th ASGCT Annual Meeting
rAIR-100 family of RNA editing research candidates demonstrated >50% RNA editing and restores wild-type AAT (M-AAT) protein levels above 30 mM with subcutaneous GalNAc delivery RESTORE+ platform proprietary chemistry and improved GalNAc delivery enhance in vivo RNA editing potency, durability, and safety AIRNA is expected to file clinical trial application for optimized product candidate (AIR-001) […]
AIRNA Appoints Jacob Elkins Chief Medical Officer
Cambridge, MA, USA and Tübingen, Germany, April 16, 2025 – AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, today announced the appointment of Jacob Elkins, M.D., as Chief Medical Officer. Dr. Elkins, an accomplished neurologist and biopharmaceutical executive, comes to AIRNA with two decades of leadership experience […]
